The new AGA Clinical Practice Update on Surveillance After Pathologically Curative Endoscopic Submucosal Dissection of Early Gastrointestinal Neoplasia in the United States: Commentary offers advice regarding surveillance intervals using endoscopy and other relevant modalities after endoscopic removal of dysplastic legions and early GI cancers with endoscopic submucosal dissection (ESD) which were deemed pathologically curative. Main takeawayPatients with malignant legions removed by curative ESD possess a higher risk of lymph node metastasis that should be surveilled more closely than those with resection dysplasia not associated with lymphatic spread.
Author: Praveen Suthrum
A number of clinical trials in noncolorectal gastrointestinal cancers have opened in recent months. Maybe one of your patients could benefit from being enrolled? Locally advanced or metastatic hepatocellular carcinoma (HCC). Adult patients with biopsy-proven advanced hepatocellular cancer who have failed on two systemic therapies are sought for a phase 2 trial testing an electromagnetic treatment device called TheraBionic. Participants will have a 1-hour session with the device at the cancer center, then will take the device home and self-administer three 1-hour treatments a day for up to 2 years, with clinic visits every 6 weeks.
The droplets patients expel during upper endoscopy and colonoscopy procedures could pose a risk for transmission of SARS-CoV-2 to health care workers involved in performing these procedures, according to a study from Beth Israel Deaconess Medical Center. Researchers created a unique portable device capable of identifying the airborne droplets that can carry SARS-CoV-2 and other viruses from one person to another.
The recent lowering of colorectal cancer (CRC)-screening age from 50 to 45 years is likely to affect demand for colonoscopy and case mix, and result in a modest lowering of adenoma-detection rate (ADR), the chief colonoscopy-quality metric, a new analysis suggests. Dr. Seth Crockett of the University of North Carolina at Chapel Hill and Dr. Uri Ladabaum of Stanford University in California modeled scenarios reflecting, a base case (before the age eligibility change), a future steady state of screening participation based on age and a temporary high influx (“bolus”) of 45-49-year-old screenees.
The FDA cleared an investigational new drug application for CYNK-101, a natural killer cell therapy for the treatment of patients with advanced HER2/neu-positive gastric or gastroesophageal junction adenocarcinoma. The clearance includes use of the investigational cell therapy in combination with chemotherapy, trastuzumab (Herceptin, Genentech) and pembrolizumab (Keytruda, Merck).
BackgroundDysbiosis of ulcerative colitis (UC) has been frequently investigated using readily accessible stool samples. However, stool samples might insufficiently represent the mucosa-associated microbiome status. We hypothesized that luminal contents including loosely adherent luminal bacteria after bowel preparation may be suitable for diagnosing the dysbiosis of UC. MethodsThis study included 16 patients with UC (9 men and 7 women, mean age: 52.13 ± 14.09 years) and 15 sex- and age-matched healthy individuals (8 men and 7 women, mean age: 50.93 ± 14.11 years). They donated stool samples before colonoscopy and underwent luminal content aspiration and endoscopic biopsy during the colonoscopy. Then, the composition of each…
What advice would you offer a junior faculty member interested in a career in medical education within gastroenterology and hepatology? Just before I completed fellowship, I asked Holly Humphrey, MD, the former dean of the Pritzker School of Medicine at the University of Chicago, this same question. Her answer was simple and is worth sharing: “In the beginning, just focus on becoming the best clinician possible. The rest will fall into place with time.” So, I did exactly this. I continually tried to push the limits of my knowledge, always questioning standard clinical practices to understand the evidence behind (or…
Gastroenterology guideline panels should avoid the use of race and ethnicity in their screening recommendations unless they are transparent about the proper context, two experts argued. These panels should consider more specific variables to determine screening criteria, but also be transparent about the implications of either using race/ethnicity or removing it from a previous recommendation in the future, wrote Shazia M. Siddique, MD, MSHP, of the University of Pennsylvania in Philadelphia, and Folasade P. May, MD, PhD, of the University of California in Los Angeles in Gastroenterology.
Host Dr. Lawrence Kosinski sits down with Laura Wingate to discuss her work as Executive Vice President, Education, Support, & Advocacy for the Crohn’s & Colitis Foundation (CCF.) To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play HealthcareNOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen Release date:7 December 2021
The US Multi-Society Task Force on Colorectal Cancer now recommends that colorectal cancer screening begin at 45 years of age. The update falls in line with recommendations from leading national cancer societies. “Although there is no literature demonstrating that CRC screening in individuals under age 50 improves health outcomes such as CRC incidence or CRC-related mortality, sufficient data … suggest average-risk CRC screening [should] begin at age 45,” wrote the authors,